CASI
Price
$1.20
Change
-$0.10 (-7.69%)
Updated
Jun 27 closing price
Capitalization
18.59M
ERAS
Price
$1.31
Change
+$0.05 (+3.97%)
Updated
Jun 27 closing price
Capitalization
364.02M
40 days until earnings call
Interact to see
Advertisement

CASI vs ERAS

Header iconCASI vs ERAS Comparison
Open Charts CASI vs ERASBanner chart's image
CASI Pharmaceuticals
Price$1.20
Change-$0.10 (-7.69%)
Volume$30.57K
Capitalization18.59M
Erasca
Price$1.31
Change+$0.05 (+3.97%)
Volume$1.89M
Capitalization364.02M
CASI vs ERAS Comparison Chart in %
Loading...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CASI vs. ERAS commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CASI is a Hold and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (CASI: $1.20 vs. ERAS: $1.28)
Brand notoriety: CASI and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CASI: 22% vs. ERAS: 122%
Market capitalization -- CASI: $18.59M vs. ERAS: $364.02M
CASI [@Biotechnology] is valued at $18.59M. ERAS’s [@Biotechnology] market capitalization is $364.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CASI’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • CASI’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than CASI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CASI’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 4 bullish TA indicator(s).

  • CASI’s TA Score: 5 bullish, 3 bearish.
  • ERAS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CASI is a better buy in the short-term than ERAS.

Price Growth

CASI (@Biotechnology) experienced а -9.43% price change this week, while ERAS (@Biotechnology) price change was -8.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

CASI is expected to report earnings on Mar 31, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($364M) has a higher market cap than CASI($18.6M). ERAS YTD gains are higher at: -48.805 vs. CASI (-57.597). CASI has higher annual earnings (EBITDA): -38.42M vs. ERAS (-150.24M). ERAS has more cash in the bank: 305M vs. CASI (12.7M). CASI has less debt than ERAS: CASI (18.5M) vs ERAS (50.8M). CASI has higher revenues than ERAS: CASI (31.4M) vs ERAS (0).
CASIERASCASI / ERAS
Capitalization18.6M364M5%
EBITDA-38.42M-150.24M26%
Gain YTD-57.597-48.805118%
P/E RatioN/AN/A-
Revenue31.4M0-
Total Cash12.7M305M4%
Total Debt18.5M50.8M36%
FUNDAMENTALS RATINGS
CASI: Fundamental Ratings
CASI
OUTLOOK RATING
1..100
89
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
95
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CASIERAS
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 25 days ago
81%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DSCLX17.350.12
+0.70%
DFA International Social Cor Eq Instl
SCUIX29.44N/A
N/A
Hartford Schroders US Small Cap Opps I
PFGKX37.20N/A
N/A
Victory Pioneer Fundamental Growth R6
PDEQX18.95N/A
N/A
PGIM Jennison Emerging Markets Eq OppsR6
NWAGX22.36N/A
N/A
Nationwide Janus Henderson Overseas A

CASI and

Correlation & Price change

A.I.dvisor tells us that CASI and ASND have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and ASND's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASI
1D Price
Change %
CASI100%
-7.69%
ASND - CASI
33%
Poorly correlated
-0.55%
RIGL - CASI
29%
Poorly correlated
+3.73%
SRPT - CASI
28%
Poorly correlated
-0.81%
AURA - CASI
27%
Poorly correlated
-0.16%
ERAS - CASI
26%
Poorly correlated
+1.98%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.98%
RVMD - ERAS
57%
Loosely correlated
-1.49%
LRMR - ERAS
54%
Loosely correlated
-2.11%
XNCR - ERAS
53%
Loosely correlated
-3.10%
ATXS - ERAS
52%
Loosely correlated
+2.94%
APGE - ERAS
52%
Loosely correlated
-0.89%
More